+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 50Years +
All Genders
ID07286214

Evaluating Two Doses of Sarilumab with Prednisone Taper for Early Polymyalgia Rheumatica A Randomized, Double-Blind, Placebo-Controlled Study

Led by Sanofi · Updated on 2026-10-21

300

Participants Needed

85

Research Sites

6 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating sarilumab, given at two different doses, for treating adults aged 50 years and older with early polymyalgia rheumatica PMR. This randomized, double-blind, placebo-controlled Phase 3 study aims to compare the effectiveness of sarilumab plus a 52-week prednisone taper against placebo plus the same prednisone taper. The purpose is to assess whether sarilumab can improve sustained remission rates and to determine its safety and tolerability in this population. Participants are assigned to one of three groups placebo with prednisone taper, sarilumab 150 mg every two weeks with prednisone taper, or sarilumab 200 mg every two weeks with prednisone taper. The prednisone taper lasts 52 weeks. The study includes an initial screening visit, baseline and randomization visit with first drug administration, multiple treatment visits every two weeks from Week 2 to Week 44, an end of treatment visit at Week 52, and a final study visit at Week 58. During the study, participants will undergo regular assessments including monitoring for remission status, flare rates, and changes in PMR activity scores. Safety will be evaluated by tracking adverse events, laboratory values, and antibody formation against the drug throughout the study period up to Week 58. Participants may also complete quality of life questionnaires during the study. The total participation time spans approximately 58 weeks.

CONDITIONS

Brief Title

Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

Research Team

T

Trial Transparency email recommended (Toll free for US & Canada)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here